Where is the live CopyMark page for USPTO serial 79016130?

The live record is at https://getcopymark.com/trademark/79016130. Use https://getcopymark.com/trademark/{serialNumber} for any 8-digit USPTO serial.

Who owns ADILNASANOVEL?

According to the public USPTO record for serial number 79016130, the listed owner(s) include: SANOVEL ILAÇ SANAYI VE TICARET ANONIM SIRKETI, SANOVEL Ilaç Sanayi ve Ticaret Anonim Sirketi, SANOVEL Ilaç Sanayi ve Ticaret Anonim Sirketi.

What is USPTO serial number 79016130?

Serial number 79016130 is the USPTO application identifier for the mark ADILNASANOVEL. It is used to track examination, publication, and registration of this trademark.

What is the current status of ADILNASANOVEL?

ADILNASANOVEL (79016130) currently shows USPTO status code 404 on the public record. This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Which trademark classes cover ADILNASANOVEL?

The public record lists International Classes: 005. Each class corresponds to categories of goods or services identified in the application or registration.

Trademark: ADILNASANOVEL Serial# 79016130 | status 404; last event DENC | Trademark Info & Attorney Guidance

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ADILNASANOVEL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner

Monitor this mark, or talk with CopyMark about this registration.

Trademark Monitoring

(312) 319-4460

Not the owner?

File a new U.S. trademark application, or speak with our attorneys.

Start a new application

(312) 319-4460

Owner

Goods and services

Class	Description	Status	First use
005	PHARMACEUTICAL AND VETERINARY PREPARATIONS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS, SKELETO-MUSCULAR DISORDERS, GENERAL INFECTIONS, VIRAL INFECTIONS, CENTRAL NERVOUS SYSTEM DISORDERS, GASTRO-INTESTINAL DISORDERS, FUNGAL DISEASES, ERECTILE DYSFUNCTION, RESPIRATORY DISEASES, ALLERGY, OPHTHALMIC DISEASES, CONTAINING ONE OR MORE OF THE FOLLOWING ACTIVE INGREDIENTS - CROMOLIN SODIUM, AMLODIPIN BESYLATE, ALENDRONATE SODIUM, CHLORAZEPATE DIPOTASSIUM ATROPINE SULPHATE, ATORVASTATIN CALCIUM, CANDESARTAN CILEXETIL, CEFTRIAXONE SODIUM, EPHEDRINE HCL, GUAIPHENESINE, ZAFIRLUKAST, DONEPEZIL HCL, DIFLUNISAL, DIPYRIDAMOLE, FAMOTIDINE, LOSARTAN POTASSIUM, HYDROCHLOROTHIAZIDE, MELOXICAM, PHENYLEPRINE HCL, FEXOFENADINE HCL, INDAPAMIDE, SULFISOXAZOLE, CLOPIDOGREL, LANSOPRAZOLE, CLARITHROMYCIN, FLURBIPROFEN, NIMESULIDE, PANTOPRAZOLE, PARACETAMOLE, PILOCARPINE HCL, LISINOPRIL, PSEUDO-EPHEDRINE HCL, CIPROFLOXACIN HCL, SERTRALINE HOL, CYCLOPENTOLATE HCL, DIHYDROERGOTOXINE METHANSULFONATE, TERBINAFINE, TIMOLOL MALEATE, TIAMPHENICOL, AZITHROMYCIN, TENOXICAM, FLUCONAZOLE, DIGOXINE, TIOCONAZOLE, DIMENHYDRINATE, QUINIDINE ABOGALACTANE SULPHATE, QUINIDINE PHENYLETHYL BARBITURATE, DILTIAZEM HCL, BUSPIRONE HCL, AMIODARONE HCL, TRAZODONE, DIFLUPREDNATE, ENOXACIN, LACTULOSE, KETOROLAC, PENTOXIFYLLINE, VITAMIN E, CHLORHEXIDINE, CETRIMIDE, PROPYPHENAZONE, CAFFEINE, CETIRIZINE, PHENYLPROPANOLAMINE, ZOLPIDEM, BACAMPICILLIN HCL, ROXITHROMYCIN, SULTAMICILLIN TOSILATE, ACETYLSALICYLIC ACID, AMPICILLIN NA, SULBACTAM NA, SILDENAFIL CITRATE, AMBROXOL HCL, RIBAVIRIN, LORATADINE, ETODOLAC, OMEPRAZOLE, OXYBUTYNIN CHLORIDE, QUINIDINE SULPHATE, OLANZAPINE, RALOXIFEN, PIOGLITAZONE, MOXIFLOXACIN, ROSIGLITAZONE, SIBUTRAMIN, CARVEDILOL, MONTELUKAST, CITALOPRAM, GLICLAZIDE, CEFACLOR, EZETIMIBE, ROFECOXIB, QUETIAPINE FUMARATE, METFORMIN HCL, ACARBOSE, CHLORPHENIRAMINE MALEATE, NATEGLINIDE, LEFLUNOMIDE, VALSARTAN, CEFAZOLIN SODIUM, DIACEREIN, PAROXETINE, LEVOFLOXACIN, LEVETIRACETAM, ZOLMITRIPTAN, GLIBENCLAMIDE, TIZANIDINE, PERINDOPRIL ERBUMINE, RAMIPRIL, CEFTAZIDIME, CEFUROXIME AXETYL, THIOCOLCHICOSIDE, ACAMPROSATE, ACETYLCYSTEINE, ALPHA CALCIDOL, ALPHA LIPOIC ACID, ARIPIPRAZOLE, ATOMOXETINE, BALSALAZIDE DISODIUM, BUTENAFINE HCL, CALCITRIOL, CARBONYL IRON, FOLIC ACID, CALCIUM CARBONATE, MAGNESIUM HYDROXIDE, CEFDINIR, CEFEPIME HCL, CEFIXIME, CEFPODOXIME PROXETIL, CEFPROZIL, CEPHALEXINE MONOHYDRATE, CICLESONIDE, CILAZAPRIL, CILOSTAZOL, CINITAPRIDE, CITICOLINE, CO-ENZYME Q1O, DARIFENASIN, DEFERIPRONE, DOTHIEPIN, DULOXETINE, ELETRIPTAN, ESCITALOPRAM, ESOMEPRAZOLE, ETORICOXIB, FELODIPINE, FENOFIBRATE, FERROUS SULPHATE, ZINC SULPHATE, FLUVASTATIN, FROVATRIPTAN, GABAPENTIN, GALANTAMINE, GEMIFLOXACIN, GINKGO BILOBA, GLIMEPRIDE, GRANISETRON, IBANDRONATE IRBESARTAN, IRON HYDROXIDE POLYMALTOSE, LAMIVUDINE, LAMOTRIGINE, LEVETIRACETAM, LETROZOLE, LINEZOLIDE, MEMANTINE HCL, METOPROLOL, MIDODRINE, MIRTAZAPINE, MIZOLASTINE, MOSAPRIDE CITRATE DIHYDRATE, MYCOPHENOLATE MOFETIL, NEBIVOLOL, NEFAZODONE, NIACIN, NITAZOXANIDE, ONDANSETRON, ORNIDAZOLE, OXCARBAZEPINE, PIMECROLIMUS, PRAVASTATIN, PREGABALIN, RABEPRAZOL, REBAMIPIDE, REPAGLINIDE, RISEDRONATE, RISPERIDONE, RIVASTIGMINE, ROSUVASTATIN, SACCHAROMYCES BOULARDII, TACROLIMUS, TADALAFIL, TANSULOSIN HCL, TAZAROTEN, TAZOBACTAM SODIUM, PIPERACILLIN SODIUM, TEGASEROD, TELITHROMYCIN, TERAZOCIN, TERIPARATIDE, TOLTERODINE TARTRATE, TOPIRAMATE, TRANDOLAPRIL, TRIMETHAZIDINE, VALACYCLOVIR, VALPROATE SODIUM, VENLAFAXINE, VORICONAZOLE, XIMELAGATRAN, ZALEPLON, ZIPRASIDONE, ZOLEDRONIC ACID; SANITARY PREPARATIONS FOR MEDICAL PURPOSES; DIETETIC FOODS ADAPTED FOR MEDICAL USE; FOOD FOR BABIES; MEDICAL PLASTERS; BANDAGES FOR DRESSINGS; MATERIAL FOR STOPPING TEETH; DENTAL WAX; DISINFECTANTS; PREPARATIONS FOR DESTROYING VERMIN; FUNGICIDES, HERBICIDES	SECTION 71 - CANCELLED	—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Date	Code	Event	What it means
Feb 5, 2016	DENC	NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED	—
Feb 5, 2016	DETH	DEATH OF INTERNATIONAL REGISTRATION	—
Jun 5, 2015	INNT	TOTAL INVALIDATION PROCESSED BY THE IB	—
Nov 1, 2014	XXSS	GENERIC MADRID TRANSACTION SENT TO IB	—
Nov 1, 2014	XXCR	GENERIC MADRID TRANSACTION CREATED	—
May 27, 2014	INTR	TOTAL INVALIDATION OF REG EXT PROTECTION CREATED	—
Sep 27, 2013	C71T	CANCELLED SECTION 71	—
Nov 3, 2012	ADCH	CHANGE OF NAME/ADDRESS REC'D FROM IB	—
May 2, 2008	FINO	FINAL DECISION TRANSACTION PROCESSED BY IB	—
Aug 23, 2007	FICS	FINAL DISPOSITION NOTICE SENT TO IB	—
Aug 23, 2007	FIMP	FINAL DISPOSITION PROCESSED	—
Aug 17, 2007	FICR	FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB	—
Jan 23, 2007	R.PR	REGISTERED-PRINCIPAL REGISTER	Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 7, 2006	PUBO	PUBLISHED FOR OPPOSITION	Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 18, 2006	NPUB	NOTICE OF PUBLICATION	—
Sep 20, 2006	PREV	LAW OFFICE PUBLICATION REVIEW COMPLETED	—
Sep 8, 2006	ALIE	ASSIGNED TO LIE	—
Sep 1, 2006	CNSA	APPROVED FOR PUB - PRINCIPAL REGISTER	—
Aug 17, 2006	ACEC	AMENDMENT FROM APPLICANT ENTERED	—
Jul 24, 2006	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
Jul 24, 2006	MAIL	PAPER RECEIVED	—
Jul 14, 2006	TCCA	TEAS CHANGE OF CORRESPONDENCE RECEIVED	—
Mar 16, 2006	RFNP	REFUSAL PROCESSED BY IB	—
Feb 22, 2006	RFCS	NON-FINAL ACTION MAILED - REFUSAL SENT TO IB	—
Feb 22, 2006	RFRR	REFUSAL PROCESSED BY MPU	—
Feb 18, 2006	RFCR	NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW	—
Feb 17, 2006	CNRT	NON-FINAL ACTION WRITTEN	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 7, 2006	DOCK	ASSIGNED TO EXAMINER	—
Nov 7, 2005	NWAP	NEW APPLICATION ENTERED	—
Nov 3, 2005	REPR	SN ASSIGNED FOR SECT 66A APPL FROM IB	—

ADILNASANOVEL